Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC), Metastatic Castration Sensitive Prostate Cancer (MCSPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT06239194
Phase: PHASE1|PHASE2
Trial Summary: This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): ModeX Therapeutics, An OPKO Health Company
Acronym:

Pin It on Pinterest